USE OF HEDIS A1C TARGETS IN CHARACTERIZING TREATMENT GOALS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) INITIATING BASAL INSULIN

被引：0

作者：

Oster, G. ^{[1
]}

Moen, D. ^{[2
]}

Yang, T. ^{[3
]}

Dalal, M. ^{[3
]}

Kazemi, M. ^{[3
]}

Sung, J. C. ^{[3
]}

Traylor, L. ^{[3
]}

Sullivan, S. D. ^{[4
]}

机构：

[1] Policy Anal Inc, Brookline, MA USA

[2] MoenMDConsulting, St Paul, MN USA

[3] Sanofi US Inc, Bridgewater, NJ USA

[4] Univ Washington, Sch Pharm, Seattle, WA 98195 USA

来源：

VALUE IN HEALTH | 2015年 / 18卷 / 03期

关键词：

D O I：

10.1016/j.jval.2015.03.407

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

PDB100

引用

页码：A70 / A70

页数：1

共 50 条

[21] HDL EFFLUX CAPACITY, AND PARTICLE REMODELLING IN PATIENTS WITH TYPE 1 DIABETES MELLITUS (T1DM) AND TYPE 2 DIABETES MELLITUS (T2DM)
Byrne, R.
Curley, S.
Ahmed, K.
Ahmed, M.
Gibney, J.
Mcgillicuddy, F.
ATHEROSCLEROSIS, 2020, 315 : E65 - E66
[22] Persistence of the Use of Initially Prescribed Basal Insulin Therapies by People with Type 2 Diabetes (T2DM)
Gordon, Jason P.
Mcewan, Phil
Home, Philip
DIABETES, 2009, 58 : A148 - A149
[23] Saxagliptin (SAXA) Reduces A1C and Is Well Tolerated in Patients With Type 2 Diabetes (T2DM) and Albuminuria
Bonora, Enzo
Cook, William
Bryzinski, Brian
Hirshberg, Boaz
Allen, Elsie
DIABETES, 2013, 62 : A669 - A669
[24] Risk Factors and Economic Burden of Hypoglycemia in Older Patients with Type 2 Diabetes Mellitus (T2DM) Initiating Basal Insulin (BI) in a US Medicare Advantage Population
Escalada, Javier
Liao, Laura
Pan, Chunshen
Wang, Hongwei
DIABETES, 2015, 64 : A254 - A254
[25] Cost-Effectiveness of Insulin Glargine and Insulin Detemir in the Basal Regimen for Naive Insulin Patients with Type 2 Diabetes Mellitus (T2DM) in Malaysia
Shafie, Asrul Akmal
Ng, Chin Hui
CLINICOECONOMICS AND OUTCOMES RESEARCH, 2020, 12 : 333 - 343
[26] Stepwise Intensification of Prandial Insulin Versus Basal-Bolus Insulin Therapy in Patients (Pts) with Type 2 Diabetes Mellitus (T2DM)
Raccah, Denis
Haak, Thomas
Huet, Dominique
Monnier, Louis
Penfornis, Alfred
Robertson, Douglas
Labard, Pascale
Soler Ramon, Juan
DIABETES, 2010, 59 : A151 - A151
[27] ACHIEVEMENT OF GLYCAEMIC TARGETS WITH CANAGLIFLOZIN IN TRIPLE THERAPY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM)
Diels, J.
Schubert, A.
Hamilton, G.
Canovatchel, W.
VALUE IN HEALTH, 2015, 18 (07) : A598 - A598
[28] Exenatide (EXE) use in T2DM with A1C ≤ 7%
Hood, Robert C.
DIABETES, 2006, 55 : A116 - A117
[29] Variability of Postprandial Hyperglycemia (PPHG) When A1C Remains ≥7.0% After Treatment of Type 2 Diabetes Mellitus (T2DM) With Oral Agents and Insulin: Implications for Prandial Treatment
Shaefer, Charles
Reid, Timothy
Digenio, Andres
Vlajnic, Aleksandra
Zhou, Rong
Riddle, Matthew
DIABETES, 2012, 61 : A611 - A612
[30] Self-Reported Goals and Challenges of Dietary Adherence in Patients with Type 2 Diabetes Mellitus (T2DM)
Traina, Shana B.
Weiser, Jonathan D.
DIABETES, 2010, 59 : A525 - A525

← 1 2 3 4 5 →